A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations
Public ClinicalTrials.gov record NCT03390504. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3 Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Subjects With Advanced Urothelial Cancer and Selected FGFR Gene Aberrations
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate efficacy of erdafitinib versus chemotherapy or pembrolizumab in participants with advanced urothelial cancer harboring selected fibroblast growth factor receptor (FGFR) aberrations who have progressed after 1 or 2 prior treatments, at least 1 of which includes an anti-programmed death ligand 1(PD-\[L\]1) agent (cohort 1) or 1 prior treatment not containing an anti-PD-(L) 1 agent (cohort 2).
Study identification
- NCT ID
- NCT03390504
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 629 participants
Conditions and interventions
Conditions
Interventions
- Erdafitinib Drug
- Vinflunine Drug
- Docetaxel Drug
- Pembrolizumab Drug
- Fibroblast Growth Factor Receptor inhibitor Clinical Trial Assay (FGFRi CTA) Device
Drug · Device
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 23, 2018 (Actual)
- Primary completion
- Apr 15, 2024 (Actual)
- Completion
- Dec 31, 2027 (Estimated)
- Last update posted
- Sep 25, 2026
2018 – 2027
United States locations
- U.S. sites
- 26
- U.S. states
- 17
- U.S. cities
- 25
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Alaska Urological Institute dba Alaska Clinical Research Center | Anchorage | Alaska | 99503 | — |
| University of Calif Davis Medical Center | Sacramento | California | 95817 | — |
| St. Helena Hospital - Martin-O'Neil Cancer Center | St. Helena | California | 94574 | — |
| MedStar Georgetown University Hospital | Washington D.C. | District of Columbia | 20007 | — |
| University of Miami Sylvester Cancer Center | Miami | Florida | 33136 | — |
| Mid Florida Hematology Oncology | Orange | Florida | 32763 | — |
| Piedmont Cancer Institute | Atlanta | Georgia | 30318-0922 | — |
| Rush University | Chicago | Illinois | 60612 | — |
| Edward Hines Jr V A Hospital | Hines | Illinois | 60141 | — |
| Norton Cancer Institute | Louisville | Kentucky | 40207 | — |
| Maryland Oncology Hematology, PA | Lanham | Maryland | 20706 | — |
| University of Michigan Health System | Ann Arbor | Michigan | 48109-5000 | — |
| VA Sierra Nevada Health Care System | Reno | Nevada | 89509 | — |
| Dartmouth Hitchcock Medical Center | Lebanon | New Hampshire | 03756 | — |
| Weill Cornell Medical College | New York | New York | 10029 | — |
| Montefiore Medical Center | The Bronx | New York | 10461 | — |
| Levine Cancer Institute, Carolinas HealthCare System | Charlotte | North Carolina | 28204 | — |
| W G Bill Hefner VA Medical Center | Salisbury | North Carolina | 28144 | — |
| Oncology Hematology Care | Cincinnati | Ohio | 45242 | — |
| The Center for Cancer and Blood Disorders | Fort Worth | Texas | 76104 | — |
| Texas Oncology-Memorial City | Houston | Texas | 77024 | — |
| MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| Texas Oncology Tyler | Tyler | Texas | 75702 | — |
| INOVA Dwiight &Martha Schar Cancer Institute | Fairfax | Virginia | 22031 | — |
| Virginia Oncology Associates | Norfolk | Virginia | 23502 | — |
| VA Puget Sound Healthcare System | Seattle | Washington | 98108 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 319 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03390504, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 25, 2026 · Synced Oct 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03390504 live on ClinicalTrials.gov.